-
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406 ·
Phase: Phase 2, Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female)
· Tennessee: Germantown, Knoxville, Nashville
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Chattanooga, Knoxville, Nashville
-
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
NCT07621614 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: Up to 25 Years ·
Sex: All (male and female)
· Tennessee: Knoxville, Memphis
-
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Chattanooga, Germantown, Nashville
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130 ·
Phase: Phase 1 ·
Ages: 16 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701 ·
Phase: Phase 1 ·
Ages: 16 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Collierville, Memphis
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
NCT04897321 ·
Phase: Phase 1 ·
Ages: Up to 21 Years ·
Sex: All (male and female)
· Tennessee: Memphis
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· Tennessee: Germantown
-
DESTINY-PANTUMOUR04
NCT07124000 ·
Phase: Not specified ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Familial Investigations of Childhood Cancer Predisposition
NCT03050268 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Tennessee: Memphis
-
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Knoxville, Nashville
-
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
NCT02775643 ·
Phase: Not specified ·
Ages: Up to 18 Years ·
Sex: All (male and female)
· Tennessee: Memphis
-
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
NCT04903119 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT07751042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NCT07555210 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Project: Every Child for Younger Patients With Cancer
NCT02402244 ·
Phase: Not specified ·
Ages: Up to 25 Years ·
Sex: All (male and female)
· Tennessee: Chattanooga, Knoxville, Memphis, Nashville
-
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
NCT06398418 ·
Phase: Phase 1 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Tennessee: Memphis, Nashville
-
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
NCT01205815 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Chattanooga, Nashville
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Tennessee: Bartlett, Nashville
-
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04485013 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Knoxville
-
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04851119 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Months to 30 Years ·
Sex: All (male and female)
· Tennessee: Memphis
-
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Tennessee: Germantown, Knoxville